Can Mounjaro Affect Your Mood?

Does Mounjaro directly cause mood changes?

The honest answer is: possibly, in a minority of people, though the picture is not yet fully clear. Tirzepatide acts on GIP and GLP-1 receptors, both of which are present not only in the gut but in areas of the brain involved in reward and mood regulation. The gut-brain axis is genuinely complex, and medicines that slow gastric emptying and reduce appetite can have ripple effects beyond blood sugar and body weight.

In the main SURMOUNT-1 clinical trial, serious psychiatric adverse events were not identified as a primary finding at any dose. That said, spontaneous post-marketing reports to regulators in several countries have described patients experiencing anxiety, low mood or emotional blunting after starting treatment. The MHRA's Black Triangle designation for Mounjaro means it is under enhanced surveillance precisely so that patterns like these can be tracked as real-world use grows.

For a fuller look at the broader side-effect profile, the Mounjaro side effects page covers everything from the common gastrointestinal effects through to the less frequent ones. This page focuses specifically on the mood question, because it is one our prescribers hear regularly and deserves a careful answer of its own. You can also read more about mood as a Mounjaro side effect in a dedicated resource.

The NHS medicines guidance for tirzepatide notes that patients should tell their doctor or pharmacist if they notice any changes in mood, behaviour or mental health while taking the medicine. That is sound, practical advice.

What kinds of mood changes have people reported?

Reports cover a range of experiences. Some patients describe a general flatness or emotional blunting, a sense that the normal highs feel muted. Others describe heightened anxiety, particularly in the first few weeks of treatment or after a dose increase. Irritability has also come up in patient accounts, sometimes attributed to changes in eating patterns, sometimes appearing to have no obvious trigger.

There is a complicating factor worth acknowledging: weight-loss journeys carry their own emotional weight. Rapid changes in appetite, food relationship and body image can themselves affect how someone feels day to day. Separating a pharmacological effect from a psychological one is genuinely difficult, and patients and prescribers both navigate that ambiguity. If you are concerned that the medicine itself may be affecting your mood, that is always a valid thing to raise.

Some patients also worry specifically about anxiety. If you have noticed worsening anxiety since starting treatment, the question of whether Mounjaro can cause anxiety attacks is covered in a separate resource, since anxiety and panic-like symptoms have their own mechanism to consider.

One practical note: rapid weight loss can sometimes affect micronutrient intake and energy levels, both of which have downstream effects on mood. Making sure protein, hydration and sleep are adequate alongside treatment matters more than many people expect.

Who is most likely to notice a mood effect, and when?

People with a personal or family history of depression, anxiety or other mood disorders are generally advised to discuss this with their prescriber before starting any GLP-1 or dual-agonist therapy. That is not a reason to rule out treatment, but it is a reason for closer monitoring during the early weeks.

Timing matters too. Mood changes, when they do occur, most often appear in the first four to eight weeks or after a dose increase, which aligns with the period when gastrointestinal side effects are also most likely. Some patients find that nausea and disrupted eating patterns in those early weeks contribute to feeling low or anxious, and that things settle as the body adjusts. That pattern is worth watching for rather than assuming the worst.

Anyone using oral contraceptives alongside Mounjaro should know that the medicine's effect on gastric emptying can reduce pill absorption in the first four weeks and for four weeks after each dose increase, a non-oral contraceptive method is recommended during those windows, per NHS guidance. Hormonal fluctuations from contraceptive changes can themselves affect mood, so it is worth keeping that variable in mind.

The pancreatitis Drug Safety Update issued by the MHRA in January 2026 is a reminder that prescribers and patients should stay alert to new symptoms, not just abdominal pain, but any unexpected change in how you feel. Read the page on Mounjaro and the pancreas if that is also on your mind.

When should you seek help, and how do you report a mood-related side effect?

If you experience low mood that persists beyond a few days, any thoughts of self-harm or suicide, or a change in mental wellbeing that feels significant, contact your GP or a clinician the same day. Do not wait for a routine follow-up. If you are in crisis, 999 or the Samaritans (116 123) are the right first call.

For milder but persistent changes, raise them at your next prescriber review. At nume, aftercare is available seven days a week, so you are not left waiting until a Monday if something comes up over the weekend. A prescriber can assess whether the mood change is likely to be medicine-related, advise on dose timing, or recommend a pause or switch if that is clinically the right step.

You can also report suspected side effects directly to the MHRA using the Yellow Card scheme, patient reports matter and contribute to the ongoing safety picture for newer medicines. This is particularly important given Mounjaro's Black Triangle status. The NHS patient guide to tirzepatide lists mental health changes among the effects to watch for and report.

If you are still weighing up whether tirzepatide is right for you, a free consultation with our prescribers gives you space to discuss your full medical history, including mental health, before anything is prescribed. That conversation is exactly what clinical assessment is for.